LifeMine is a biopharmaceutical company pioneering Top-Down Drug Discovery™, a bold new approach that leverages evolutionary insights from fungi to unearth next-generation precision medicines. Through our data-immersive and technologically expansive discovery engine, we are uniquely positioned to bring mechanistically and structurally novel precision medicines to patients in urgent need of breakthrough disease intervention. LifeMine’s initial pipeline programs are focused in organ transplantation and antifungals. The Company is headquartered in Cambridge, MA, with offices in Gloucester, MA and Basel, Switzerland.
$175M sweet spot round size
2017
$175M
from 2 investors over 1 rounds
LifeMine Therapeutics raised $175M on April 23, 2022
Investors: Fidelity and + 6 Other investors